Skip to main content

UBS Keeps Their Buy Rating on United Therapeutics (UTHR)

Tipranks - Tipranks - Wed Jan 7, 8:00AM CST

UBS analyst Ashwani Verma maintained a Buy rating on United Therapeutics today and set a price target of $645.00.

Claim 70% Off TipRanks Premium

Verma covers the Healthcare sector, focusing on stocks such as Insmed, ACADIA Pharmaceuticals, and Exelixis. According to TipRanks, Verma has an average return of 12.7% and a 57.26% success rate on recommended stocks.

Currently, the analyst consensus on United Therapeutics is a Moderate Buy with an average price target of $534.50.

See Insiders’ Hot Stocks on TipRanks >>

Based on United Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $799.5 million and a net profit of $338.7 million. In comparison, last year the company earned a revenue of $748.9 million and had a net profit of $309.1 million

Based on the recent corporate insider activity of 246 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year. Last month, Louis Sullivan, a Director at UTHR sold 5,950.00 shares for a total of $3,047,156.93.

Read More on UTHR:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).